Walleye Capital LLC Fibrogen Inc Transaction History

Walleye Capital LLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$0.89 - $2.36 $12,454 - $33,025	-13,994 Reduced 9.27%	136,953 $121,000
Q1 2024 May 15, 2024	BUY	$0.73 - $2.73 $110,191 - $412,085	150,947 New	150,947 $354,000
Q4 2022 Feb 14, 2023	SELL	$13.27 - $17.73 $37,912 - $50,654	-2,857 Reduced 10.16%	25,263 $404,000
Q3 2022 Nov 14, 2022	SELL	$11.4 - $14.6 $1.78 Million - $2.28 Million	-156,286 Reduced 84.75%	28,120 $366,000
Q2 2022 Aug 08, 2022	BUY	$7.94 - $12.96 $208,941 - $341,042	26,315 Added 16.65%	184,406 $1.95 Million
Q1 2022 May 16, 2022	BUY	$12.02 - $16.79 $1.46 Million - $2.04 Million	121,582 Added 333.02%	158,091 $1.9 Million
Q4 2021 Mar 03, 2022	SELL	$9.93 - $15.39 $2.07 Million - $3.2 Million	-208,205 Reduced 85.08%	36,509 $514,000
Q3 2021 Nov 15, 2021	BUY	$10.18 - $26.64 $2.49 Million - $6.52 Million	244,714 New	244,714 $2.5 Million
Q1 2020 May 15, 2020	SELL	$23.3 - $45.96 $11,650 - $22,980	-500 Closed	0 $0
Q4 2019 Feb 14, 2020	SELL	$34.58 - $48.06 $42,049 - $58,440	-1,216 Reduced 70.86%	500 $22,000
Q3 2019 Nov 14, 2019	BUY	$36.98 - $48.45 $50,810 - $66,570	1,374 Added 401.75%	1,716 $63,000
Q2 2019 Aug 14, 2019	BUY	$35.13 - $55.53 $12,014 - $18,991	342 New	342 $15,000

47.1M

387K

672K

Ticker FGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 93,741,200
Market Cap $32.8M
Description
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic k...

Get notified when there are updates to the investment portfolio of Walleye Capital LLC, based on Form 13F filings with the SEC.

Stay updated on Walleye Capital LLC with notifications on news.